History of Surgery in Hilar Cholangiocarcinoma
Executive Summary
Hilar cholangiocarcinoma, commonly referred to as a "Klatskin tumor" following Dr. Gerald Klatskin’s landmark 1965 report, remains a technically challenging malignancy due to its central location in the liver hilum and proximity to major vascular structures. Historically, the disease was often overlooked during surgery, with patient mortality typically resulting from biliary obstruction and subsequent liver failure rather than metastatic spread.
Modern management has shifted from purely palliative measures toward aggressive surgical resection as the only potential cure. Key findings in current clinical practice include:
The Primacy of R0 Resection: Achieving histologically negative margins is the most significant modifiable factor for long-term survival. This often necessitates major hepatic resection and concomitant caudate lobectomy.
Spread Patterns: The tumor demonstrates significant longitudinal spread (up to 20 mm) and perineural invasion (75% of cases), making localized bile duct excision inadequate for most patients.
Preoperative Management: While routine preoperative biliary drainage is controversial due to increased infection risks, Portal Vein Embolization (PVE) is a critical tool for inducing hypertrophy in the future liver remnant (FLR) to prevent postoperative failure.
Advanced Modalities: Liver transplantation, once considered contraindicated, is showing promise under strict protocols (e.g., the Mayo protocol) involving neoadjuvant chemoradiation for unresectable cases.
Historical Context and Diagnostic Evolution
The formal identification of hilar cholangiocarcinoma dates back to 1840 (Durand-Fardel), but its distinct clinical manifestations were not emphasized until Dr. Klatskin’s 1965 study of 13 patients. Klatskin noted that while these tumors were frequently missed during laparotomy, palliative internal drainage could restore health for significant periods because the disease often remains localized to the biliary tree.
The evolution of surgical treatment has coincided with advancements in biliary imaging:
1918–1924: First uses of contrast to visualize bile ducts and the gallbladder.
1952–1975: Development of percutaneous transhepatic cholangiography (PTBD), which became safer with the 1975 introduction of the "skinny needle" technique.
1968–1970: Introduction of endoscopic retrograde cholangiopancreatogram (ERCP) and the cannulation of the ampulla of Vater.
Surgical Strategies: Local vs. Hepatic Resection
The Limitations of Local Resection
Early surgical attempts focused on local bile duct resection with hepaticojejunostomy. However, data suggests this approach is largely inadequate:
Insufficient Margins: Invasive filtration spreads 6–10 mm, while superficial spread reaches 10–20 mm. Achieving an R0 resection (negative margins) requires gross surgical margins of 1–2 cm.
Invasive Characteristics: Approximately 80% of tumors extend into the liver parenchyma, and 30% involve the portal vein.
Exceptions: Local resection is only considered appropriate for small papillary tumors (Bismuth-Corlette type I) confined to the bile duct wall (Tis or T1).
The Case for Aggressive Hepatic Resection
Over the last two decades, major hepatic resection has become the standard for achieving curative R0 status.
Caudate Lobe Involvement: The caudate lobe ducts join near the confluence, leading to tumor involvement in 40–98% of patients. Concomitant caudate lobe resection is now widely adopted to decrease local recurrence.
Resection Rates: Studies indicate that the R0 resection rate increases in direct correlation with the rate of associated liver resections.
Survival and Mortality Trends
While liver resection historically carried higher perioperative mortality (15% vs. 8% for local resection in 1990), modern improvements in perioperative care have narrowed this gap. Some specialized centers now report zero mortality for hepatobiliary resections. The 5-year survival rates for surgically resected patients vary from 25% to 40%.
Preoperative Management and Staging
1. Biliary Drainage
The routine use of preoperative biliary drainage to relieve jaundice is controversial.
Risks: Systematic reviews indicate no reduction in mortality and a significant increase in postoperative infectious complications and sepsis.
Selective Use: It remains valuable for specific subsets, such as patients with biliary sepsis, severe malnutrition, or those requiring a prolonged delay before surgery.
2. Portal Vein Embolization (PVE)
PVE is utilized when the anticipated future liver remnant (FLR) is less than 40% of the total liver volume. By inducing hypertrophy in the FLR, PVE permits curative resection in patients who would otherwise be considered unresectable due to the risk of postoperative liver failure.
3. Staging Laparoscopy
Despite modern imaging, 40–50% of patients explored with curative intent are found to be unresectable during laparotomy. Staging laparoscopy, often combined with laparoscopic ultrasound, can identify occult metastases in 25–42% of cases, preventing unnecessary major surgery.
Advanced and Experimental Surgical Modalities
Vascular Resection
Combined portal vein resection and reconstruction is sometimes performed as part of a "no-touch" resection. While some retrospective studies suggest this does not increase mortality and may improve survival in R0 cases, results remain conflicting, and randomized clinical trials are required.
Liver Transplantation (OLT)
Initially, OLT for hilar cholangiocarcinoma was abandoned due to poor 5-year survival (28–30%) and early recurrence. However, the "Mayo protocol" has renewed interest in OLT for unresectable cases or those arising from primary sclerosing cholangitis. This protocol requires:
Neoadjuvant chemoradiation.
Strict staging laparotomy to rule out nodal disease.
Highly selective inclusion criteria.
Mesohepatectomy (Minor Liver Resection)
As an alternative to major trisectionectomy, some centers utilize "minor" liver resections of segments 4, 5, and 1. This strategy aims to preserve sufficient hepatic mass in jaundiced patients. In selected cases, this approach has achieved zero mortality and 5-year survival rates (34%) comparable to major resection.
Ex Situ Ex Vivo Resection
This extreme procedure involves removing the liver, resecting the tumor outside the body, and autotransplanting the remnant. While technically feasible, results have generally been poor due to the liver's reduced tolerance for ischemia following long-standing cholestasis.
Prognostic Factors
The primary goal of surgery is the achievement of negative histologic margins. Other factors positively impacting long-term survival include:
Lack of nodal involvement (nodal spread beyond the hepatoduodenal ligament usually renders the tumor unresectable).
Well-differentiated tumor grade.
Papillary tumor morphology.
Absence of perineural invasion.
Lower AJCC T stage.
